Inventor · disambiguated record
Alan Gill
Also filed as: GILL ALAN · GILL ALAN P
15 granted patents·6 pending applications·86 citations·filing 2000–2025
91Inventor score
Files withALS THERAPY DEVELOPMENT INST10ALS THERAPY DEV INST3PERRIN STEVEN2AMATUCCI ALDO1BIOGEN IDEC INC1
Top patents by PatentIndex Score
21 records- 0195US11692040B2Anti-CD40L antibodies and methods for treating CD40L-related diseases or disordersALS THERAPY DEVELOPMENT INST·Filed 2021·Granted Jul 4, 2023·4 cites·8 claims
- 0295US11014990B2Anti-CD40L antibodiesALS THERAPY DEVELOPMENT INST·Filed 2020·Granted May 25, 2021·6 cites·10 claims
- 0393US10683356B2Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodiesALS THERAPY DEVELOPMENT INST·Filed 2018·Granted Jun 16, 2020·8 cites·4 claims
- 0490US10106618B2Anti-CD40L antibodiesALS THERAPY DEVELOPMENT INST·Filed 2017·Granted Oct 23, 2018·8 cites·9 claims
- 0590US7472695B2Controller for air intake heaterPHILLIPS & TEMRO IND INC·Filed 2005·Granted Jan 6, 2009·20 cites·13 claims
- 0688US8435514B2Method for the treatment of neurodegenerative diseasesPERRIN STEVEN·Filed 2009·Granted May 7, 2013·17 cites·1 claims
- 0787US9044459B2Method for the treatment of neurodegenerative diseasesALS THERAPY DEV INST·Filed 2013·Granted Jun 2, 2015·8 cites·4 claims
- 0885US12275793B2Anti-CD40L antibodies and methods for treating CD40L-related diseases or disordersALS THERAPY DEVELOPMENT INST·Filed 2023·Granted Apr 15, 2025·0 cites·11 claims
- 0980US6495525B1VLA-4 inhibitor: oMePUPA-VBIOGEN INC·Filed 2000·Granted Dec 17, 2002·13 cites·19 claims
- 1078US11708349B2Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditionsALS THERAPY DEVELOPMENT INST·Filed 2019·Granted Jul 25, 2023·1 cites·13 claims
- 1177US12157728B2Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditionsALS THERAPY DEVELOPMENT INST·Filed 2023·Granted Dec 3, 2024·0 cites·15 claims
- 1275US2025263493A1Anti-cd40l antibodies and methods for treating cd40l-related diseases or disordersALS THERAPY DEVELOPMENT INST·Filed 2025·Application pending·0 cites
- 1366US2024016879A1Copper complexes for treatment of neurodegenerative disordersALS THERAPY DEVELOPMENT INST·Filed 2023·Application pending·0 cites
- 1461US11660324B2Copper complexes for treatment of neurodegenerative disordersALS THERAPY DEVELOPMENT INST·Filed 2020·Granted May 30, 2023·0 cites·14 claims
- 1560US8865645B2Method of treating lung fibrosis using ST2 polypeptideAMATUCCI ALDO·Filed 2007·Granted Oct 21, 2014·1 cites·11 claims
- 1654US8946301B2Targeting of T-lymphocytes to treat amyotrophic lateral sclerosisALS THERAPY DEV INST·Filed 2012·Granted Feb 3, 2015·0 cites·13 claims
- 1746US8673308B2Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseasesPERRIN STEVEN·Filed 2012·Granted Mar 18, 2014·0 cites·17 claims
- 1843US2006134102A1Lymphotoxin beta receptor agents in combination with chemotherapeutic agentsBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 1940US2006196484A1Capture and burn air heaterGILL ALAN P·Filed 2006·Application pending·0 cites
- 2037US2016186706A1Systems and methods for fuel state control with fuel recirculation and preheatBRAZIL GREEN ENERGY TECHNOLOGIES LLC·Filed 2015·Application pending·0 cites
- 2137US2017231558A1Measurement Of ALS Progression Based On Kinetic DataALS THERAPY DEV INST·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alan Gill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →